AbbVie (ABBV -0.3%) gets a breakthrough therapy designation from the FDA for its...

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

AbbVie (ABBV -0.3%) gets a breakthrough therapy designation from the FDA for its investigational, all-oral, genotype 1 hepatitis C direct-acting antiviral (DAA) combo regimen (with and without ribavirin). Shareholders of Enanta Pharmaceuticals (ENTA -1%) should take note: one of the three DAAs in the combo treatment is the protease inhibitor ABT-450. ENTA is entitled to $195M in regulatory milestone payments on the DAA, as well as additional royalties on any revenue.